Is lonis Pharmaceuticals, Inc. (IONS) Among the Best Genomics Stocks to Buy According to Analysts?

On May 28, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said spouse GSK reported pivotal Phase 3 information for bepirovirsen. The corp disclosed a 19% functional cure complaint arsenic compared to 0% connected modular care, portion reaching 26% successful patients with little viral activity. The trials, B-Well 1 and B-Well 2, met superior endpoints. Ionis stated that 233 of 1,220 treated patients achieved a functional cure versus nary successful the placebo group.

The institution besides reported 49% of treated patients reached aboveground antigen levels ≤100 IU/mL 1 twelvemonth post-treatment, portion 23% achieved sustained viral suppression astatine week 72.

Ionis mentioned adverse events included injection tract reactions and impermanent liver enzyme hikes.

Chief Executive Officer Brett P. Monia called the information "an important advance," stating bepirovirsen could code chronic hepatitis B by reducing viral replication and suppressing aboveground antigen arsenic good arsenic stimulating an immune response.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is simply a steadfast that is progressive successful the improvement and selling of quality therapeutic drugs utilizing antisense technology.

While we admit the imaginable of IONS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.